Studies on the tight-binding nature of tolcapone inhibition of soluble and membrane-bound rat brain Catechol-O-methyltransferase

Journal of Pharmacology and Experimental Therapeutics

Volumn 282, Issue 2, 1997, Pages 812-817

  Borges, Nuno ^a   Vieira Coelho, Maria Augusta ^a,b   Parada, Antonio ^a   Soares Da Silva, Patrício ^a,b  

^a DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

^b Inst of Pharmacol and Therapeutics   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE; TOLCAPONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; BRAIN HOMOGENATE; COMPETITIVE INHIBITION; CONTROLLED STUDY; ENZYME INHIBITION; MALE; MICHAELIS CONSTANT; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BENZOPHENONES; BRAIN; CATECHOL O-METHYLTRANSFERASE; CELL MEMBRANE; ENZYME INHIBITORS; MALE; NITROPHENOLS; PROTEIN BINDING; RATS; RATS, WISTAR;

EID: 0030746313     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. AXELROD, J. AND TOMCHICK, R.: Enzymatic O-methylation of epinephrine and other catechols. J. Biol. Chem. 233: 702-705, 1958.
2. BRADFORD, M. M.: A rapid method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254, 1976.
3. CHA, S.: Tight binding inhibitors. I. Kinetic behavior. Biochem. Pharmacol. 24: 2177-2185, 1975.
4. DAVIS, T. I., ROZNOSKI, M. AND BURNS, R. S.: Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline. Mov. Dis. 10: 349-351, 1995.
5. DINGEMANSE, J., JORGA, K. M., SCHMITT, M., GIESCHKE, R., FOTTELER, B., ZURCHER, G., DA PRADA, M. AND VAN BRUMMELEN, P.: Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. Clin. Pharmacol. Ther. 57: 508-517, 1995.
6. FLEMSTROM, G. AND SAFSTEN, B.: Role of dopamine and other stimuli of mucosal bicarbonate secretion in duodenal protection. Dig. Dis. Sci. 39: 1839-1842, 1994.
7. GULDBERG, H. AND MARSDEN, C.: Catechol-O-methyl transferase: Pharmacological aspects and physiological role. Pharmacol. Rev. 27: 135-206, 1975.
8. KAAKKOLA, S., GORDIN, A. AND MANNISTO, P. T.: General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase. Gen. Pharmacol. 25: 813-824, 1994a.
9. KAAKKOLA, S., TERAVAINEN, H., AHTILA, S., RITA, H. AND GORDIN, A.: Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology 44: 77-80, 1994b.
10. KOPIN, I. J.: Catecholamine metabolism: Basic aspects and clinical significance. Pharmacol. Rev. 37: 333-364, 1985.
11. LOTTA, T., VIDGREN, J., TILGMANN, C., ULMANEN, I., MELEN, K., JULKUNEN, I. AND TASKINEN, J.: Kinetics of human soluble and membrane-bound catechol O-methyltransferase - a revised mechanism and description of the them labile variant of the enzyme. Biochemistry 34: 4202-4210, 1995.
12. MAJ, J., ROGÓZ, Z., SKUZA, G., SOWINSKA, H. AND SUPERATA, J.: Behavioral and neurochemical effects of Ro 40-7592, a new COMT inhibitor with a potential therapeutic activity in Parkinson's disease. J. Neural. Trans. 2: 101-112, 1990.
13. MANNISTO P., KAAKKOLA, S., NISSINEN, E., LINDEN, I. B. AND POHTO, P.: Properties of novel effective and highly selective inhibitors of catechol-O-methyltransferase. Life Sci. 43: 1465-1471, 1988.
14. MANNISTO, P. T. AND KAAKKOLA, S.: Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease. Pharmacol. Toxicol. 66: 317-323, 1990.
15. MANNISTO, P. T., LANG, A., RAUHALA, P. AND VASAR, E.: Beneficial effects of co-administration of catechol-O-methyltransferase inhibitors and L-dihydroxyphenylalanine in rat models of depression. Eur. J. Pharmacol. 274: 229-233, 1995.
16. MOREAU, J.-L., BORGULYA, J., JENCK, F. AND MARTIN, J. R.: Tolcapone: A potential new antidepressant detected in a novel animal model of depression. Behav. Pharmacol. 5: 344-350, 1994.
17. MOTULSKY, H. G., SPANNARD, P. AND NEUBIG, R.: GraphPad Prisms. San Diego: GraphPad Prism Software Inc., 1994.
18. NISSINEN., E., LINDÉN, I., SCHULTZ, E. AND POHTO, P.: Biochemical and pharmacological properties of peripherally acting catechol-O-methyltransferase inhibitor Entacapone. Naunyn-Schmiedeberg's Arch. Pharmacol. 346: 262-266, 1992.
19. NISSINEN, E., TUOMINEN, R., PERHONIEMI, V. AND KAAKKOLA, S.: Catechol-O-methyltransferase activity in human and rat small intestine. Life Sci. 42: 2609-2614, 1988.
20. RAUTELIN, H., RENKONEN, O. V. AND KOSUNEN, T. V.: In vitro susceptibility of Helicobacter pylori to nitecapone. Eur. J. Clin. Microbiol. Infec. Dis. 11: 274-275, 1992.
21. ROBERTS, J. W., CORA-LOCATELLI, G., BRAVI, D., AMANTEA, M. A., MOURADIAN, M. M. AND CHASE, T. N.: Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in Parkinsonian patients. Neurology 43: 2685-2688, 1993.
22. ROTH, J.: Membrane-bound catechol-O-methyltransferase: A reevaluation of its role in the O-methylation of the catecholamine neurotransmitters. Rev. Physiol. Biochem. Pharmacol. 120: 1-29, 1992.
23. VIDGREN, J., SVENSSON, L. A. AND LILJAS, A.: Crystal structure of catechol O-methyltransferase. Nature (Lond.) 368: 354-358, 1994.
24. VIEIRA-COELHO, M. A. AND SOARES-DA-SILVA, P.: Ontogenic aspects of liver and kidney catechol-O-methyltransferase sensitivity to tolcapone. Br. J. Pharmacol. 117: 516-520, 1996.
25. ZURCHER, G., COLZI, A, AND DA PRADA, M.: Ro 40-7592: Inhibition of COMT in rat brain and extracerebral tissues. J. Neural Trans. 32: 375-380, 1990.
26. ZURCHER, G., DINGEMANSE, J. AND DA PRADA, M.: Potent COMT inhibition by Ro 40-7592 in the periphery and in the brain. Preclinical and clinical findings. Adv. Neurol. 60: 641-647, 1993.